ERBB2 and breast cancer: Using a next generation sequencing (NGS) targeted gene expression approach, we aim to identify a transcriptional signature associated with SLNs metastases, in order to identify new biomarkers related to tumor-microenvironment interplay in SLNs of patients with Luminal HER2 negative BC and thereby improve OSNA prognostic information.